STERO Biotechs Ltd.

STERO Ltd., founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatments and solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy.

STERO’s patent was ISSUED! In the US on August 2018.
The patent exceptional strength is mainly due to its’ extremely wide coverage.

Stero has commenced several clinical trials:

  • our phase 2a clinical trials, on steroid dependent Crohn’s disease (IBD) started on Q1 2020, in Chronic Urticaria (Hives) started on Q3 2020.
  • our phase 1/2 clinical trial treating severe covid19 patients has started on Q1 2021!

additional clinical trial is planned for 2021 for more indications in the pipeline.

STERO addresses multiple huge market opportunities. Steroids are the first line of treatment of many conditions, such as inflammatory and autoimmune diseases, including AutoImmune Hepatitis, rheumatoid arthritis, lupus, IBD, COPD, psoriasis and more.

Stero’s abilities to lower the steroid dosage needed, allowing refractory patients to receive steroid treatments and enhancing the current steroid treatments are all around groundbreaking